RecruitingNCT05702502

Assessing the Presence of CT-DNA in Lymphoma Associated HLH

Liquid Biopsy for the Identification of Malignancy Associated Haemophagocytic Lymphohistiocytosis (HLH)


Sponsor

Nottingham University Hospitals NHS Trust

Enrollment

12 participants

Start Date

Jun 30, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose. The most common cause of HLH in adults is lymphoma (blood cancer). Outcomes for adults with HLH and cancer are serious, and most die after days or weeks because they have been diagnosed or treated too late. It is likely that many cases where patients died of HLH with no underlying cause actually had cancer. Recently it has been found that patients with certain types of lymphoma have DNA which comes directly from their cancer (circulating tumour DNA; ctDNA). Aggressive lymphomas release a lot of ctDNA which can be detected in the blood of patients. This study will look for ctDNA in patients with HLH, and see if it is possible to use it to diagnose lymphoma earlier. Patients will provide a small additional blood sample for analysis. Diagnosing lymphoma more rapidly would mean more people could get the correct treatment for the lymphoma which has caused their HLH. They could receive the correct treatment sooner. Earlier diagnosis and treatment could improve survival for these patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for tumor DNA circulating in the blood (called ctDNA or liquid biopsy) in patients with a serious inflammatory condition called HLH (hemophagocytic lymphohistiocytosis) that is associated with lymphoma. The goal is to understand whether this blood test can help diagnose and monitor the underlying lymphoma causing HLH. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of HLH - You have been on high-dose steroids and/or cancer treatment for fewer than 72 hours for this episode of HLH - You may be included if you have a known or relapsed lymphoma along with HLH **You may NOT be eligible if...** - The cause of your HLH is already known to be non-cancerous (e.g., a viral or autoimmune cause) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Nottingham Univeristy Hospitals NHS Trust

Nottingham, Nottinghamshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05702502


Related Trials